Table 1.
Effects of prodrugs and control compounds on the viability of selected cancer and normal cells lines expressed as half-maximal inhibitory concentration (IC50, μM).
| Prodrug or Control | IC50/BL-2 Cells i (μM) | ||
|---|---|---|---|
| 24 h ii | 48 h ii | 96 h ii | |
| 5 | 5 ± 1 | 5 ± 1 | 8 ± 1 |
| 12 | 2 ± 1 | 0.5 ± 0.2 | 0.3 ± 0.1 |
| 9 | 37 ± 2 | 35 ± 2 | 33 ± 2 |
| 7 | − | >25 | − |
| 13 | − | 35 ± 6 | − |
| 11 | >50 | >50 | >50 |
| Fe(HQ)2 iii | 3 ± 1 | 3 ± 1 | 3 ± 1 |
| IC50/A2780 cells i (μM) | |||
| 24 h ii | 48 h ii | 96 h ii | |
| 5 | 10 ± 3 | 5 ± 2 | 5 ± 2 |
| 9 | 42 ± 3 | 32 ± 3 | 30 ± 5 |
| 7 | − | >25 | − |
| 13 | − | >50 | − |
| 11 | >50 | >50 | >50 |
| Fe(HQ)2 | 3 ± 1 | 3 ± 1 | 3 ± 1 |
| IC50/DU-145 cells i (μM) | |||
| 24 h ii | 48 h ii | 96 h ii | |
| 5 | 20 ± 3 | 10 ± 2 | 10 ± 2 |
| 9 | >50 | 47 ± 2 | 35 ± 3 |
| 11 | >50 | >50 | >50 |
| Fe(HQ)2 | 3 ± 1 | 3 ± 1 | 3 ± 1 |
| IC50 (μM) | |||
| Jurkat cells i | HDFa cells i48 h ii | ||
| 24 h ii | 48 h ii | ||
| 5 | 20 ± 3 | 20 ± 2 | 18 ± 5 |
| 12 | − | − | <1 |
| 9 | 30 ± 3 | 30 ± 4 | >50 |
| 11 | >50 | >50 | − |
i Burkitt lymphoma cell line: BL-2; Human ovarian cell line: A2780; human prostate cell line: DU-145; human immortalized T lymphocyte cells: Jurkat; human dermal fibroblasts, adult: HDFa. ii Times of incubation of the prodrugs and controls with corresponding cells. iii Fe(HQ)2: 1 to 2 mixture of FeCl3 and 8-hydroxyquinoline.